> For the complete documentation index, see [llms.txt](https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/llms.txt). Markdown versions of documentation pages are available by appending `.md` to page URLs; this page is available as [Markdown](https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/evidence-summary.md).
# Evidence Summary
WFA is one of the most extensively studied natural anticancer compounds in preclinical research. The mechanistic literature is broad, replicated across multiple labs, and unusually coherent for a plant-derived compound.
That does not make it clinically established. The central limitation remains unchanged: direct human efficacy data for purified WFA is missing.
### How strong is the evidence overall?
The evidence is strongest in three areas.
* **Cell biology:** extensive across breast, ovarian, lung, glioblastoma, colorectal, prostate, lymphoma, and other models.
* **Animal studies:** meaningful in vivo support exists across several tumour types.
* **Mechanistic depth:** autophagy blockade, HSP90 disruption, ER-α suppression, vimentin targeting, CSC depletion, and immune effects all have specific experimental backing.
The evidence is weakest in direct clinical efficacy. Human work so far is limited to pharmacokinetic studies, safety-oriented oncology data, and whole-extract trials that do not isolate WFA exposure.
### Research overview
More than 300 peer-reviewed papers have examined WFA's anticancer activity. Publication volume has accelerated in recent years. Important contributions come from groups working on autophagy blockade, ER-α biology, ovarian cancer stem cell targeting, and checkpoint inhibitor sensitisation.
A key reason WFA remains credible is that the signal is not based on one fragile finding. Several independent groups have reproduced core themes, especially around apoptosis, EMT suppression, HSP90 interference, and autophagic flux disruption.
### Clinical application status
#### Published human oncology data
The only published Phase I oncology study evaluated oral WFA in advanced high-grade osteosarcoma. It confirmed pharmacokinetic exposure and tolerability in cancer patients. It was not designed to prove efficacy.
Liver enzyme elevation was the most common adverse event. That finding makes liver monitoring essential when WFA is used at pharmacologic intensity.
#### Ongoing human combination work
The most advanced current clinical study is an ovarian cancer trial combining Ashwagandha extract with liposomal doxorubicin. This is useful for translational relevance, but it is still not a purified-WFA efficacy trial.
#### Whole-extract human data
Some breast cancer data with whole Ashwagandha extract plus chemotherapy is encouraging. It does not establish WFA efficacy because the formulation, WFA content, and exposure are not controlled in a way that isolates WFA as the active variable.
**IMPORTANT:** Please do not assume that any “ashwagandha” supplement will provide oncology‑relevant WFA exposure. This page was created to highlight Withaferin A‑focused targets, and specialised WFA‑standardised leaf extracts are required, not general ashwagandha root products. For support in sourcing see the **Sourcing Quality** page within this WFA in Oncology Hub.
### Key strengths
* **Pleiotropic:** WFA hits multiple cancer hallmarks rather than one narrow target.
* **Resistance-relevant:** it engages EMT, CSC biology, HSP90 networks, and inflammatory survival signalling.
* **Selective in preclinical work:** cancer cells tend to show greater vulnerability than normal cells.
* **Pharmacokinetically flexible:** its short half-life makes pulsing more realistic than with hydroxychloroquine.
### Key limitations
* Oral bioavailability is poor in standard formulations. See [Sourcing page](/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/sourcing-quality.md) for Liposomal formula.
* Oncology dose-response relationships come from cell and animal studies.
* No head-to-head human comparison against standard therapy exists.
* Long-term safety at oncology-relevant WFA exposure is not established.
* Human efficacy data for purified or liposomal WFA is absent.
### Bottom line
WFA is a serious adjunctive research candidate, not a speculative curiosity. The strongest case for it comes from its relevance to resistance biology, not from generic antioxidant language or broad herbal tradition.
At the same time, the gap between mechanistic promise and clinical proof is real. WFA should be viewed as investigational, especially when used in high-potency, bioavailability-enhanced forms.
### Related pages
* [Anticancer Mechanisms](/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/anti-cancer-mechanisms.md)
* [Pharmacokinetics & Metabolism](/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/pharmacokinetics-and-metabolism.md)
* [Safety & Interactions](/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/safety-interactions-and-wfa-dosing.md)
### Key references
Kakar S. et al. — preclinical pleiotropic anticancer profile of withaferin A.\
Koduru S. et al. — comprehensive mechanistic and translational review of withaferin A.\
Muniraj N. et al. — autophagy blockade and energetic impairment in breast cancer.\
Sehdev V. et al. — ER-α suppression and ER signalling effects in breast cancer.\
Bolleddula J. et al. — Phase I safety and pharmacokinetics in advanced high-grade osteosarcoma.\
University of Louisville — ovarian cancer trial of Ashwagandha extract plus liposomal doxorubicin.\
Kandhare A. et al. — human pharmacokinetics and bioequivalence of *Withania somnifera* extracts.\
Therapeutic Goods Administration — safety advisory on medicines containing *Withania somnifera*.\
Access and availability:\
Source: MCS Formulas, “Withaferin A Pro Liposomal.”\
`50 mg` WFA per capsule. Available via healthcare professional request.\
### In this section
#### Core pages
* [Withaferin A (WFA) in Oncology](/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology.md)
* [Evidence Summary](/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/evidence-summary.md)
* [Anticancer Mechanisms](/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/anti-cancer-mechanisms.md)
* [Immune Effects](/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/immune-effects.md)
* [Synergistic Combinations](/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/synergistic-combinations.md)
#### Cancer-type pages
* [WFA Evidence by Cancer Type](/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/wfa-evidence-by-cancer-type.md)
* [Breast Cancer](/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/wfa-evidence-by-cancer-type/breast-cancer.md)
* [Ovarian Cancer](/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/wfa-evidence-by-cancer-type/ovarian-cancer.md)
* [Non-Small Cell Lung Cancer](/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/wfa-evidence-by-cancer-type/non-small-cell-lung-cancer.md)
* [Glioblastoma](/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/wfa-evidence-by-cancer-type/glioblastoma.md)
* [Other Cancer Types](/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/wfa-evidence-by-cancer-type/other-cancer-types.md)
#### Practical pages
* [Pharmacokinetics & Metabolism](/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/pharmacokinetics-and-metabolism.md)
* [Sourcing Quality](/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/sourcing-quality.md)
* [Safety, Interactions and WFA Dosing](/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/safety-interactions-and-wfa-dosing.md)
* [Hormones — ER-α and Androgens](/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/hormones-er-a-and-androgens.md)
* [Terrain Support — Liposomal WFA vs Whole-Plant Ashwagandha](/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/terrain-support-liposomal-wfa-vs-whole-plant-ashwagandha.md)
{% hint style="warning" %}
This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use.
{% endhint %}
{% hint style="info" %}
© 2026 Abbey Mitchell. All rights reserved. Please share by URL rather than copying page text.
{% endhint %}
---
# Agent Instructions
This documentation is published with GitBook. GitBook is the documentation platform designed so that both humans and AI agents can read, navigate, and reason over technical content effectively. Learn more at gitbook.com.
## Querying This Documentation
If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question.
Perform an HTTP GET request on the current page URL with the `ask` query parameter, and the optional `goal` query parameter:
```
GET https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/evidence-summary.md?ask=&goal=
```
`ask` is the immediate question: it should be specific, self-contained, and written in natural language.
`goal` is optional and describes the broader end goal you are ultimately trying to accomplish on behalf of the user. GitBook uses it to tailor the answer towards what is most useful for that goal.
The response will contain a direct answer to the question and relevant excerpts and sources from the documentation.
Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.